Hyundai Bio announced on the 11th that it has started the administration of phase 2 clinical trials, including the announcement of the recruitment of COVID-19 patients, for CP-COV03, an oral antiviral drug candidate developed as a general treatment for COVID-19 and viruses.
The start of the dosing procedure means that although dosing has not yet started, actual preparations for dosing have begun, such as preparations to recruit patients and consultation with the administration institution.
CP-COV03 is an innovative general-purpose antiviral agent with pharmacological action that allows cells to remove all viruses by promoting the ‘autophagy’ action in which the cells recognize the virus as a foreign substance and remove it by itself when the virus penetrates into the cell. .
A Hyundai Bio official said, “The discovery of a mechanism to kill bacteria and the discovery of a substance that exerts that mechanism led to the birth of the 20th century medicine called penicillin.” It will be the first general-purpose drug in the field of viruses.”
Seok Ji-heon, reporter for Money Today Broadcasting MTN